METTL1 and acute myeloid leukemia: When subjected to cytarabine (CYT) treatment, METTL1 knockdown AML cells exhibited a significantly diminished proliferation capacity and increased susceptibility to cytarabine-induced cell death (Fig. 2L, M and Additional file 2: Fig S2A, B).